Advances in preclinical investigation of prostate cancer gene therapy

Molecular Therapy

Volumn 15, Issue 6, 2007, Pages 1053-1064

  Figueiredo, Marxa L ^a,b   Kao, Chinghai ^c   Wu, Lily ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CG 7870; CONDITIONALLY REPLICATING ADENOVIRUS; CV 706; CV 787; CYTOSINE DEAMINASE; DENDRITIC CELL VACCINE; DEPSIPEPTIDE; DOCETAXEL; FAS LIGAND; FLUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HEAT SHOCK PROTEIN 70; INTERLEUKIN 24; KALLIKREIN; NITROREDUCTASE; ONCOLYTIC ADENOVIRUS; ONYX 015; OSTEOCALCIN; PACLITAXEL; PROBASIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN P53; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; LOW DRUG DOSE; MOLECULAR IMAGING; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; PROSTATE CANCER; REPORTER GENE; REVIEW; SUICIDE GENE THERAPY; TREATMENT OUTCOME; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; VIRAL GENE THERAPY;

ANIMALS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS;

EID: 34249315474     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300181     Document Type: Review

References (148)

1. National Cancer Institute, D, Surveillance Research Program, Cancer Statistics Branch (released April 2005, based on the November 2004 submission). Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002).
2. Genetic Modification Clinical Research Information System, M.C.R.I.S. .
3. Aumuller, G, Seitz, J, Lilja, H, Abrahamsson, PA, von der Kammer, H and Scheit, KH (1990). Species- and organ-specificity of secretory proteins derived from human prostate and seminal vesicles. Prostate 17 31-40.
4. Cleutjens, KB, van Eekelen, CC, van der Korput, HA, Brinkmann, AO and Trapman, J (1996). Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271: 6379-6388.
5. Huang, W, Shostak, Y, Tarr, P, Sawyers, C and Carey, M (1999). Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem 274: 25756-25768.
6. Wu, L, Matherly, J, Smallwood, A, Adams, JY, Billick, E, Belldegrun, A et al. (2001). Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther 8: 1416-1426.
7. Zhang, L, Adams, JY, Billick, E, Ilagan, R, Iyer, M, Le, K et al. (2002). Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther 5: 223-232.
8. Mitchell, SH, Murtha, PE, Zhang, S, Zhu, W and Young, CY (2000). An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene. Mol Cell Endocrinol 168: 89-99.
9. Yu, DC, Sakamoto, GT and Henderson, DR (1999). Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 59 1498-1504.
10. Xie, X, Zhao, X, Liu, Y, Young, CY, Tindall, DJ, Slawin, KM et al. (2001). Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum Gene Ther 12: 549-561.
11. Yousef, GM and Diamandis, EP (2002). Expanded human tissue kallikrein family - a novel panel of cancer biomarkers. Tumour Biol 23: 185-192.
12. Kasper, S, Rennie, PS, Bruchovsky, N, Sheppard, PC, Cheng, H, Lin, L et al. (1994). Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem 269: 31763-31769.
13. Zhang, X, Lee, C, Ng, PY, Rubin, M, Shabsigh, A and Buttyan, R (2000). Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate 43: 278-285.
14. Latham, JP, Searle, PF, Mautner, V and James, ND (2000). Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector. Cancer Res 60 334-341.
15. Feldman, BJ and Feldman, D (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
16. Sato, M, Johnson, M, Zhang, L, Gambhir, SS, Carey, M and Wu, L (2005). Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin Cancer Res 11: 3743-3749.
17. Yeung, F, Law, WK, Yeh, CH, Westendorf, JJ, Zhang, Y, Wang, R et al. (2002). Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 277: 2468-2476.
18. Fair, WR, Israeli, RS and Heston, WD (1997). Prostate-specific membrane antigen. Prostate 32: 140-148.
19. Chung, LW, Baseman, A, Assikis, V and Zhau, HE (2005). Molecular insights into prostate cancer progression: The missing link of tumor microenvironment. J Urol 173: 10-20.
20. Koeneman, KS, Yeung, F and Chung, LW (1999). Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39: 246-261.
21. Lian, JB, Stein, GS, Stein, JL and van Wijnen, AJ (1999). Regulated expression of the bone-specific osteocalcin gene by vitamins and hormones. Vitam Horm 55: 443-509.
22. Hsieh, CL, Yang, L, Miao, L, Yeung, F, Kao, C, Yang, H et al. (2002). A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors. Cancer Res 62: 3084-3092.
23. Huang, WC, Xie, Z, Konaka, H, Sodek, J, Zhau, HE and Chung LW (2005). Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: Role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 65: 2303-2313.
24. Gleave, M, Hsieh, JT, Gao, CA, von Eschenbach, AC and Chung LW (1991). Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51: 3753-3761.
25. Festuccia, C, Bologna, M, Gravina, GL, Guerra, F, Angelucci, A, Villanova, I et al. (1999). Osteoblast conditioned media contain TGF-β1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer 81: 395-403.
26. Wu, HC, Hsieh, JT, Gleave, ME, Brown, NM, Pathak, S and Chung, LW (1994). Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 57: 406-412.
27. Thalmann, GN, Anezinis, PE, Chang, SM, Zhau, HE, Kim, EE, Hopwood, VL et al. (1994). Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: 2577-2581.
28. Chung, LW (1995). The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surv 23: 33-42.
29. Rhee, HW, Zhau, HE, Pathak, S, Multani, AS, Pennanen, S, Visakorpi, T et al. (2001). Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel. In Vitro Cell Dev Biol Anim 37: 127-140.
30. Koeneman, KS, Kao, C, Ko, SC, Yang, L, Wada, Y, Kallmes, DF et al. (2000). Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 18: 102-110.
31. Horoszewicz, JS, Kawinski, E and Murphy, GP (1987). Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7: 927-935.
32. O'Keefe, DS, Uchida, A, Bacich, DJ, Watt, FB, Martorana, A, Molloy, PL et al. (2000). Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 45: 149-157.
33. Silver, DA, Pellicer, I, Fair, WR, Heston, WD and Cordon-Cardo, C (1997). Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3: 81-85.
34. Tsui, KH, Wu, L, Chang, PL, Hsieh, ML and Juang, HH (2004). Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular kallikrein genes. J Urol 172: 2029-2034.
35. Lee, SJ, Zhang, Y, Lee, SD, Jung, C, Li, X, Kim, HS et al. (2004). Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther 10: 1051-1058.
36. Cheng, WS, Kraaij, R, Nilsson, B, van der Weel, L, de Ridder, CM, Totterman, TH et al. (2004). A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol Ther 10: 355-364.
37. Nettelbeck, DM, Jerome, V and Muller, R (2000). Gene therapy: Designer promoters for tumour targeting. Trends Genet 16: 174-181.
38. Qiao, J, Doubrovin, M, Sauter, BV, Huang, Y, Guo, ZS, Balatoni, J et al. (2002). Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther 9: 168-175.
39. Sato, M, Johnson, M, Zhang, L, Zhang, B, Le, K, Gambhir, SS et al. (2003). Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol Ther 8: 726-737.
40. Segawa, T, Takebayashi, H, Kakehi, Y, Yoshida, O, Narumiya, S and Kakizuka, A (1998). Prostate-specific amplification of expanded polyglutamine expression: A novel approach for cancer gene therapy. Cancer Res 58: 2282-2287.
41. Johnson, M, Sato, M, Burton, J, Gambhir, SS, Carey, M and Wu, L (2005). Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: The advantage of a cell-specific transcriptional targeting approach. Mol Imaging 4: 463-472.
42. Ilagan, R, Zhang, LJ, Pottratz, J, Le, K, Salas, S, Iyer, M et al. (2005). Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model. Mol Cancer Ther 4: 1662-1669.
43. Block, A, Milasinovic, D, Mueller, J, Schaefer, P, Schaefer, H and Greten, H (2002). Amplified Muc1-specific gene expression in colon cancer cells utilizing a binary system in adenoviral vectors. Anticancer Res 22: 3285-3292.
44. Wang, Y, Iyer, M, Annala, A, Wu, L, Carey, M and Gambhir, SS (2006). Noninvasive indirect imaging of vascular endothelial growth factor gene expression using bioluminescence imaging in living transgenic mice. Physiol Genomics 24: 173-180.
45. Woraratanadharm, J, Rubinchik, S, Yu, H, Fan, F, Morrow, SM and Dong, JY (2004). Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop. Gene Ther 11: 1399-1407.
46. Sato, Y, Tanaka, K, Lee, G, Kanegae, Y, Sakai, Y, Kaneko, S et al. (1998). Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. Biochem Biophys Res Commun 244: 455-462.
47. Yoshimura, I, Ikegami, S, Suzuki, S, Tadakuma, T and Hayakawa, M (2002). Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. J Urol 168: 2659-2664.
48. Ikegami, S, Tadakuma, T, Suzuki, S, Yoshimura, I, Asano, T and Hayakawa, M (2002). Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jpn J Cancer Res 93: 1154-1163.
49. Ikegami, S, Tadakuma, T, Ono, T, Suzuki, S, Yoshimura, I, Asano, T et al. (2004). Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer. Cancer Sci 95: 367-370.
50. Kaczmarczyk, SJ and Green, JE (2003). Induction of cre recombinase activity using modified androgen receptor ligand binding domains: A sensitive assay for ligand-receptor interactions. Nucleic Acids Res 31: E86.
51. Stevenson, M, Hale, AB, Hale, SJ, Green, NK, Black, G, Fisher, KD et al. (2007). Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins. Cancer Gene Ther 14: 335-345.
52. Bonsted, A, Engesaeter, BO, Hogset, A, Maelandsmo, GM, Prasmickaite, L, D'Oliveira, C et al. (2006). Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor. J Gene Med 8: 286-297.
53. Kraaij, R, van Rijswijk, AL, Oomen, MH, Haisma, HJ and Bangma, CH (2005). Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro. Prostate 62: 253-259.
54. Massoud, TF and Gambhir, SS (2003). Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev 17: 545-580.
55. Iyer, M, Sato, M, Johnson, M, Gambhir, SS and Wu, L (2005). Applications of molecular imaging in cancer gene therapy. Curr Gene Ther 5 607-618.
56. Oliver, S, Bubley, G and Crumpacker, C (1985). Inhibition of HSV-transformed murine cells by nucleoside analogs, 2′-NDG and 2′-nor-cGMP: Mechanisms of inhibition and reversal by exogenous nucleosides. Virology 145: 84-93.
57. Freeman, SM, Whartenby, KA, Freeman, JL, Abboud, CN and Marrogi, AJ (1996). In situ use of suicide genes for cancer therapy. Semin Oncol 23: 31-45.
58. Tjuvajev, JG, Finn, R, Watanabe, K, Joshi, R, Oku, T, Kennedy, J et al. (1996). Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: A potential method for monitoring clinical gene therapy. Cancer Res 56: 4087-4095.
59. Tjuvajev, JG, Avril, N, Oku, T, Sasajima, T, Miyagawa, T, Joshi, R et al. (1998). Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 58: 4333-4341.
60. Tjuvajev, JG, Chen, SH, Joshi, A, Joshi, R, Guo, ZS, Balatoni, J et al. (1999). Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res 59: 5186-5193.
61. Gambhir, SS, Barrio, JR, Wu, L, Iyer, M, Namavari, M, Satyamurthy, N et al. (1998). Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med 39: 2003-2011.
62. Gambhir, SS, Barrio, JR, Herschman, HR and Phelps, ME (1999). Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol 26: 481-490.
63. Gambhir, SS, Herschman, HR, Cherry, SR, Barrio, JR, Satyamurthy, N, Toyokuni, T et al. (2000). Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2: 118-138.
64. Iyer, M, Wu, L, Carey, M, Wang, Y, Smallwood, A and Gambhir, SS (2001). Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci USA 98 14595-14600.
65. Kokoris, MS and Black, ME (2002). Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci 11: 2267-2272.
66. Kokoris, MS, Sabo, P and Black, ME (2000). In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy. Anticancer Res 20: 959-963.
67. Gambhir, SS, Bauer, E, Black, ME, Liang, Q, Kokoris, MS, Barrio, JR et al. (2000). A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA 97: 2785-2790.
68. 14C]FIAU for imaging of HSV1-tk reporter gene expression: Adenoviral infection vs stable transfection. Eur J Nucl Med Mol Imaging 30 1547-1560.
69. Penuelas, I, Mazzolini, G, Boan, JF, Sangro, B, Marti-Climent, J, Ruiz, M et al. (2005). Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128: 1787-1795.
70. Chung, JK (2002). Sodium iodide symporter: Its role in nuclear medicine. J Nucl Med 43: 1188-1200.
71. Dai, G, Levy, O and Carrasco, N (1996). Cloning and characterization of the thyroid iodide transporter. Nature 379: 458-460.
72. Filetti, S, Bidart, JM, Arturi, F, Caillou, B, Russo, D and Schlumberger, M (1999). Sodium/iodide symporter: A key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141: 443-457.
73. Shimura, H, Haraguchi, K, Miyazaki, A, Endo, T and Onaya, T (1997). Iodide uptake and experimental 1311 therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I-symporter gene. Endocrinology 138: 4493-4496.
74. Haberkorn, U, Henze, M, Altmann, A, Jiang, S, Morr, I, Mahmut, M et al. (2001). Transfer of the human Nal symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 42: 317-325.
75. Groot-Wassink, T, Aboagye, EO, Glaser, M, Lemoine, NR and Vassaux, G (2002). Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 13: 1723-1735.
76. Groot-Wassink, T, Aboagye, EO, Wang, Y, Lemoine, NR, Reader, AJ and Vassaux, G (2004). Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 9: 436-442.
77. Mandell, RB, Mandell, LZ and Link, CJ Jr. (1999). Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 59: 661-668.
78. Cho, JY, Shen, DH, Yang, W, Williams, B, Buckwalter, TL, La Perle, KM et al. (2002). In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther 9: 1139-1145.
79. Spitzweg, C, O'Connor, MK, Bergert, ER, Tindall, DJ, Young, CY and Morris, JC (2000). Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 60: 6526-6530.
80. Barton, KN, Paielli, D, Zhang, Y, Koul, S, Brown, SL, Lu, M et al. (2006). Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther 13: 347-356.
81. Dwyer, RM, Schatz, SM, Bergert, ER, Myers, RM, Harvey, ME, Classic, KL et al. (2005). A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther 12: 835-841.
82. Tarassoff, CP, Arlen, PM and Gulley, JL (2006). Therapeutic vaccines for prostate cancer. Oncologist 11: 451-462.
83. Mabjeesh, NJ, Zhong, H and Simons, JW (2002). Gene therapy of prostate cancer: Current and future directions. Endocr Relat Cancer 9 115-139.
84. Simons, JW, Mikhak, B, Chang, JF, DeMarzo, AM, Carducci, MA, Lim, M et al. (1999). Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59: 5160-5168.
85. Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543.
86. Michael, A, Ball, G, Quatan, N, Wushishi, F, Russell, N, Whelan, J et al. (2005). Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 11: 4469-4478.
87. Arlen, PM, Gulley, JL, Todd, N, Lieberman, R, Steinberg, SM, Morin, S et al. (2005). Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 174: 539-546.
88. Gulley, JL, Arlen, PM, Bastian, A, Morin, S, Marte, J, Beetham, P et al. (2005). Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11: 3353-3362.
89. Kaufman, HL, Wang, W, Manola, J, DiPaola, RS, Ko, YJ, Sweeney, C et al. (2004). Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22: 2122-2132.
90. Ragde, H, Cavanagh, WA and Tjoa, BA (2004). Dendritic cell based vaccines: Progress in immunotherapy studies for prostate cancer. J Urol 172: 2532-2538.
91. Murphy, GP, Tjoa, BA, Simmons, SJ, Rogers, MK, Kenny, GM and Jarisch, J (2000). Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 43: 59-62.
92. Lodge, PA, Jones, LA, Bader, RA, Murphy, GP and Salgaller, ML (2000). Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial. Cancer Res 60: 829-833.
93. Barrou, B, Benoit, G, Ouldkaci, M, Cussenot, O, Salcedo, M, Agrawal, S et al. (2004). Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53: 453-460.
94. Heiser, A, Coleman, D, Dannull, J, Yancey, D, Maurice, MA, Lallas, CD et al. (2002). Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109: 409-417.
95. Burch, PA, Croghan, GA, Gastineau, DA, Jones, LA, Kaur, JS, Kylstra, JW et al. (2004). Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase 2 trial. Prostate 60: 197-204.
96. Small, EJ, Fratesi, P, Reese, DM, Strang, G, Laus, R, Peshwa, MV et al. (2000). Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18: 3894-3903.
97. Lipinski, KS, Pelech, S, Mountain, A, Irvine, AS, Kraaij, R, Bangma, CH et al. (2006). Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity. Cancer Immunol Immunother 55 347-354.
98. Voelkel-Johnson, C, King, DL and Norris, JS (2002). Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 9: 164-172.
99. Ng, CP, Zisman, A and Bonavida, B (2002). Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/ TRAIL-mediated apoptosis of prostate cancer cells: Role of XIAP in resistance. Prostate 53: 286-299.
100. Vanoosten, RL, Moore, JM, Ludwig, AT and Griffith, TS (2005). Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 11: 542-552.
101. Rubinchik, S, Wang, D, Yu, H, Fan, F, Luo, M, Norris, JS et al. (2001). A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol Ther 4: 416-426.
102. Lebedeva, IV, Sarkar, D, Su, ZZ, Kitada, S, Dent, P, Stein, CA et al. (2003). Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 22: 8758-8773.
103. Saito, Y, Miyahara, R, Gopalan, B, Litvak, A, Inoue, S, Shanker, M et al. (2005). Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated-7 (mda-7)/interleukin-24 (IL-24) gene. Cancer Gene Ther 12: 238-247.
104. Su, Z, Emdad, L, Sauane, M, Lebedeva, IV, Sarkar, D, Gupta, P et al. (2005). Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene 24: 7552-7566.
105. Satoh, T, Timme, TL, Saika, T, Ebara, S, Yang, G, Wang, J et al. (2003). Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther 14: 91-101.
106. Rodriguez, R, Schuur, ER, Lim, HY, Henderson, GA, Simons, JW and Henderson, DR (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57: 2559-2563.
107. Chen, Y, DeWeese, T, Dilley, J, Zhang, Y, Li, Y, Ramesh, N et al. (2001). CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 61: 5453-5460.
108. DeWeese, TL, van der Poel, H, Li, S, Mikhak, B, Drew, R, Goemann, M et al. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61: 7464-7472.
109. Yu, DC, Chen, Y, Seng, M, Dilley, J and Henderson, DR (1999). The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 59: 4200-4203.
110. Dilley, J, Reddy, S, Ko, D, Nguyen, N, Rojas, G, Working, P et al. (2005). Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 12: 715-722.
111. Yu, DC, Chen, Y, Dilley, J, Li, Y, Embry, M, Zhang, H et al. (2001). Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 61: 517-525.
112. Reid, TR, Freeman, S, Post, L, McCormick, F and Sze, DY (2005). Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 12: 673-681.
113. Nemunaitis, J, Khuri, F, Ganly, I, Arseneau, J, Posner, M, Vokes, E et al. (2001). Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19: 289-298.
114. Mulvihill, S, Warren, R, Venook, A, Adler, A, Randlev, B, Heise, C et al. (2001). Safety and feasibility of injection with an E1B-55 kda gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial. Gene Ther 8: 308-315.
115. Morley, S, MacDonald, G, Kirn, D, Kaye, S, Brown, R and Soutar, D (2004). The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res 10: 4357-4362.
116. Khuri, FR, Nemunaitis, J, Ganly, I, Arseneau, J, Tannock, IF, Romel, L et al. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885.
117. Hecht, JR, Bedford, R, Abbruzzese, JL, Lahoti, S, Reid, TR, Soetikno, RM et al. (2003). A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 9: 555-561.
118. Ganly, I, Kirn, D, Eckhardt, G, Rodriguez, GI, Soutar, DS, Otto, R et al. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798-806.
119. Harada, JN and Berk, AJ (1999). p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 73: 5333-5344.
120. Goodrum, FD and Ornelles, DA (1998). p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 72: 9479-9490.
121. Edwards, SJ, Dix, BR, Myers, CJ, Dobson-Le, D, Huschtscha, L, Hibma, M et al. (2002). Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol 76: 12483-12490.
122. Rothmann, T, Hengstermann, A, Whitaker, NJ, Scheffner, M and zur Hausen, H (1998). Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol 72: 9470-9478.
123. O'Shea, CC, Johnson, L, Bagus, B, Choi, S, Nicholas, C, Shen, A et al. (2004). Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6: 611-623.
124. Lee, SJ, Kim, HS, Yu, R, Lee, K, Gardner, TA, Jung, C et al. (2002). Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther 6: 415-421.
125. Matsubara, S, Wada, Y, Gardner, TA, Egawa, M, Park, MS, Hsieh, CL et al. (2001). A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 61: 6012-6019.
126. Zhao, XY and Feldman, D (2001). The role of vitamin D in prostate cancer. Steroids 66: 293-300.
127. Getzenberg, RH, Light, BW, Lapco, PE, Konety, BR, Nangia, AK, Acierno, JS et al. (1997). Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50: 999-1006.
128. Li, X, Zhang, YP, Kim, HS, Bae, KH, Stantz, KM, Lee, SJ et al. (2005). Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Res 65: 1941-1951.
129. Sauthoff, H, Hu, J, Maca, C, Goldman, M, Heitner, S, Yee, H et al. (2003). Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: Virus persists and spreads systemically at late time points. Hum Gene Ther 14: 425-433.
130. Harrison, D, Sauthoff, H, Heitner, S, Jagirdar, J, Rom, WN and Hay, JG (2001). Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved-deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum Gene Ther 12: 1323-1332.
131. Shen, BH and Hermiston, TW (2005). Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther 12: 902-910.
132. Pipiya, T, Sauthoff, H, Huang, YQ, Chang, B, Cheng, J, Heitner, S et al. (2005). Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther 12: 911-917.
133. Tollefson, AE, Ryerse, JS, Scaria, A, Hermiston, TW and Wold, WS (1996). The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants. Virology 220: 152-162.
134. Doronin, K, Kuppuswamy, M, Toth, K, Tollefson, AE, Krajcsi, P, Krougliak, V et al. (2001). Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 75: 3314-3324.
135. Jin, F, Xie, Z, Kuo, CJ, Chung, LW and Hsieh, CL (2005). Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy. Cancer Gene Ther 12: 257-267.
136. Liu, XY, Qiu, SB, Zou, WG, Pei, ZF, Gu, JF, Luo, CX et al. (2005). Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther 11: 531-541.
137. Uckert, W, Kammertons, T, Haack, K, Qin, Z, Gebert, J, Schendel, DJ et al. (1998). Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther 9 855-865.
138. Freytag, SO, Paielli, D, Wing, M, Rogulski, K, Brown, S, Kolozsvary, A et al. (2002). Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 54: 873-885.
139. Xie, Y, Gilbert, JD, Kim, JH and Freytag, SO (1999). Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy. Clin Cancer Res 5: 4224-4232.
140. Ali, S, King, GD, Curtin, JF, Candolfi, M, Xiong, W, Liu, C et al. (2005). Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 65: 7194-7204.
141. Freytag, SO, Rogulski, KR, Paielli, DL, Gilbert, JD and Kim, JH (1998). A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9: 1323-1333.
142. Kim, JH, Kim, SH, Brown, SL and Freytag, SO (1994). Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res 54: 6053-6056.
143. Khil, MS, Kim, JH, Mullen, CA, Kim, SH and Freytag, SO (1996). Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res 2: 53-57.
144. Freytag, SO, Stricker, H, Pegg, J, Paielli, D, Pradhan, DG, Peabody, J et al. (2003). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63: 7497-7506.
145. Kubo, H, Gardner, TA, Wada, Y, Koeneman, KS, Gotoh, A, Yang, L et al. (2003). Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 14: 227-241.
146. Adams, JY, Johnson, M, Sato, M, Berger, F, Gambhir, SS, Carey, M et al. (2002). Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 8: 891-897.
147. Zhang, Y, Yu, J, Unni, E, Shao, TC, Nan, B, Snabboon, T et al. (2002). Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB. Hum Gene Ther 13: 2051-2064.
148. Furuhata, S, Ide, H, Miura, Y, Yoshida, T and Aoki, K (2003). Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer. Mol Ther 7: 366-374.